Macrogenics, Inc.

Robyn Gerena

Leslie Sydnor Johnson

Ling Ling Huang

The present invention relates to antibodies or fragments thereof that specifically bind Fc&#x3b3;RIIB, particularly human Fc&#x3b3;RIIB, with greater affinity than the antibodies or fragments thereof bind Fc&#x3b3;RIIA, particularly human Fc&#x3b3;RIIA. The present invention also provides the use of an anti-Fc&#x3b3;RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

Growing community of inventors

Frederick, MD, United States of America

Robyn Gerena